RAINFOL-01 (Rina-S)
A next-generation folate-receptor ADC that works even in tumours with low folate receptor, with responses in both ovarian and endometrial cancer.
Ovarian cohort: confirmed ORR 55.6% at 120 mg/m² (n=20) and 22.7% at 100 mg/m² (n=22) with long follow-up; endometrial cohort (n=64, after anti-PD-1 and platinum): ORR 50% at 100 mg/m² including complete responses, earning Breakthrough Therapy designation. Phase 3 RAINFOL-02 in platinum-resistant ovarian cancer is enrolling, with primary completion expected in 2027. Unlike mirvetuximab, benefit is not restricted to FRα-high tumours.
- 55.6 out of 100 people had their tumour shrink with Rina-S.
- 50 out of 100 people had their tumour shrink with Rina-S.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Advanced ovarian and endometrial cancer, heavily pretreated: rinatabart sesutecan (FRα ADC, exatecan payload) across FRα expression levels. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- ProductLuveltamab tazevibulin
Shares Folate receptor alpha, Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- IdeaSequence folate-receptor ADCs by payload class
Shares Rinatabart sesutecan, Folate receptor alpha, Ovarian cancer.
- InstitutionStephenson Cancer Center, OU Health
Shares Folate receptor alpha, Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- TrialMIRASOL / GOG-3045
Shares Folate receptor alpha, Ovarian cancer, Antibody-drug conjugate (ADC).
- TargetMUC16 (CA-125)
Shares Folate receptor alpha, Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductPuxitatug samrotecan
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).
- ProductPafolacianine
Shares Folate receptor alpha, Ovarian cancer.
- CompanyMersana Therapeutics
Shares Endometrial cancer, Ovarian cancer, Antibody-drug conjugate (ADC).